On April 3, 2017, the U.S. Food and Drug Administration approved AUSTEDO™ (deutetrabenazine), manufactured by Teva Pharmaceuticals. AUSTEDO™ is indicated for the treatment of chorea associated with Huntington’s Disease.
Teva Pharmaceuticals has elected to distribute AUSTEDO™ through three select pharmacies. PharMerica is pleased to inform you that it has been selected by Teva Pharmaceuticals as one of those pharmacies.
AUSTEDO™ has been clinically shown to decrease the Total Maximal Chorea Score in patients by 4.4 points based on the Unified Huntington’s Disease Rating Scale (UHDRS).
AUSTEDO™ has a Black Box Warning for DEPRESSION AND SUICIDALITY, for increasing the risk of depression and suicidal thoughts and behavior. Balance risks of depression and suicidality with the clinical need for treatment of chorea when considering the use of AUSTEDO™.
Tardive dyskinesia (TD) is a disorder that involves involuntary movements. The movements most often affect the lower face. Tardive means delayed and dyskinesia means abnormal movement.
Huntington’s Disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability (cognition).
Source: US National Library of Medicine
If your facility is presently treating any resident diagnosed with Huntington’s Disease or Tardive Dyskinesia and their attending physician desires to prescribe them AUSTEDO™, PharMerica is ready to assist your facility in securing this medication for your resident. We look forward to helping you.
To order an AUSTEDO™ prescription please
contact PharMerica by phone at 1-800-678-7575 press
option #3, or fax at 1-844-602-0231.